Potential differences between real-life and randomized controlled trial populations in chronic myeloid leukemia

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F25%3A00082972" target="_blank" >RIV/65269705:_____/25:00082972 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/25:00142837

Výsledek na webu

<a href="https://link.springer.com/article/10.1007/s00277-025-06703-5" target="_blank" >https://link.springer.com/article/10.1007/s00277-025-06703-5</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s00277-025-06703-5" target="_blank" >10.1007/s00277-025-06703-5</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Potential differences between real-life and randomized controlled trial populations in chronic myeloid leukemia

Popis výsledku v původním jazyce

Randomized clinical trials (RCTs) are the cornerstone of evidence-based medicine. Their findings shape everyday clinical practice by guiding the development and use of new therapeutic agents, improving patient outcomes, and forming the basis of evidence-based clinical guidelines. To ensure that these findings are robust and reliable, strict adherence to study protocols is essential. During the screening process, patients must meet all inclusion criteria and none of the exclusion criteria. This methodology helps to protect vulnerable populations-such as those with significant comorbidities or on concomitant medication-and ensures data consistency and validity. However, such stringent selection criteria may exclude many patients typically seen in daily practice, resulting in underrepresentation of real-world populations, and risk introducing inadequate generalizability of the trial results.

Název v anglickém jazyce

Potential differences between real-life and randomized controlled trial populations in chronic myeloid leukemia

Popis výsledku anglicky

Randomized clinical trials (RCTs) are the cornerstone of evidence-based medicine. Their findings shape everyday clinical practice by guiding the development and use of new therapeutic agents, improving patient outcomes, and forming the basis of evidence-based clinical guidelines. To ensure that these findings are robust and reliable, strict adherence to study protocols is essential. During the screening process, patients must meet all inclusion criteria and none of the exclusion criteria. This methodology helps to protect vulnerable populations-such as those with significant comorbidities or on concomitant medication-and ensures data consistency and validity. However, such stringent selection criteria may exclude many patients typically seen in daily practice, resulting in underrepresentation of real-world populations, and risk introducing inadequate generalizability of the trial results.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

<a href="/cs/project/LX22NPO5102" target="_blank" >LX22NPO5102: Národní ústav pro výzkum rakoviny</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Annals of Hematology

ISSN

0939-5555

e-ISSN

1432-0584

Svazek periodika

104

Číslo periodika v rámci svazku

11

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

4

Strana od-do

6105-6108

Kód UT WoS článku

001608353100001

EID výsledku v databázi Scopus

2-s2.0-105020886322